Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

L2, L23 ribosomal proteins, guidelines for medical management of OA and, 1547
L-696,418 N-carboxyalkyl synthetic matrix metalloproteinase inhibitor, stromelysin degradation of cartilage and, 1678
La antigens
antibodies to synovial antigens in early RA and, 1418
in human skin, 1271
Labial salivary glands, minor, E-selectin in, in SSc, 406
Laboratory costs, related to drugs in RA, 318
Laboratory testing, evaluative, disease activity and, 1555
Lacrimal gland, cognitive deficit in rheumatic diseases and, 1363
Lactation, immunosuppressive drugs during pregnancy and, 1722
Lactoferrin, antineutrophil cytoplasmic antibodies in SLE and, 633
[gl] light chain, human monoclonal antiphospholipid antibody and, 1068
Lambda phage expression library, anti-apolipoprotein A1 in SLE, 1655
Lansbury articular index, in study of stromelysin-1 and TIMP-1 in RA, 969
Large granular lymphocytes, in hematology of Felty's syndrome, 1252
Large vessel vasculitis, fatal, in lupus pregnancy, 710
L-arginine, lipoxin A4, nitric oxide and, in polymorphonuclear neutrophil vascular cytotoxicity, 768
Larsen scores, hand bone mineral density in RA and, 1204
Latent self epitopes, guidelines for medical management of OA and, 1547
Latent transcription factors, early response genes and, 877
Lateral tibiofemoral compartment, directed examination of, to predict cartilage abnormalities, 917
Lavage, arthroscopic, guidelines for medical management of OA and, 1535
Learning disabilities, cognitive deficit in rheumatic diseases and, 1363
Lectins, carbohydrate in RA immune complexes and, 744
Leflunomide, in active RA, 1595
Leg ergonometry, cardiovascular health and fitness in end-stage OA and, 799
Lesions
annular erythematous, in cutaneous LE from ultraviolet emissions from a photocopier, 1152
autoimmune, autoimmune sialadenitis in Sjogren's syndrome and, 1077
brain, cognitive deficit in rheumatic diseases and, 1363
calcific, in calcinosis treated with diltiazem, 1646
cartilage, 1290
erythema migrans, Lyme borreliosis and, 565
erythematous ulcerating, 1161
finger, 1157
finger tendon, in RA, ultrasonography of, 786
inflammatory, 306, 877, 1077
joint, 678
lytic, in spinal involvement in gout, 139
OA, 201, 1290
in RA, 242, 678
renal morphologic, 242
skin, 184, 1152, 1161, 1271
in spinal involvement in gout, 139
Leu, MHC class II genes, anti-U1 snRNP antibody and, 396
Leucine
T cell receptors in RA and, 577
zipper region, autoepitopes of 52-kd SS-A/Ro and, 990
Leukemia
HTLV and, 458, 690
immunosuppressive drugs during pregnancy and, 1722
Leukoagglutination tranfusion reactions, IgG receptors in autoimmune disease and, 306
Leukocytes
antiinflammatory effects of adenosine regulators and, 1040
blood DNA, COL2A1 gene mutations in chondrodysplasias and familial OA and, 999
cytokines in JRA and, 211
IgG receptors in autoimmune disease and, 306
pseudoseptic inflammatory knee effusion in sickle cell disease and, 284
Leukopenia, parvovirus B19 infection, chronic fatigue syndrome and, 638
Leuprolide, pregnancy and, 1722
Lewis rats
antigen-induced arthritis and type II collagen in, 1092
radiographic changes in adjuvant arthritis in, 129
Ligaments
annular, carpal tunnel syndrome due to T cell lymphoma and, 1707
anterior cruciate, 420, 525, 1290
fibular collateral, 201
joint and connective tissue ultrasonography of, 736
in OA, 201, 420, 525, 1290
sesamoid, 201
Ligands
cytokines, early response genes and, 877
HLA-B39 and, in AS and pauciarticular JRA , 1672
human monoclonal antiphospholipid antibody and, 1068
T cell receptors in RA and, 577
Light chain
antibodies to synovial antigens in early RA and, 1418
DNA binding of IgM[gl] anti-DNA antibody and, 389
[gl], human monoclonal antiphospholipid antibody and, 1068
Light microscopy
in RA, 1192, 1618
to study pseudoseptic inflammatory knee effusion in sickle cell disease, 284
Limited cutaneous SSc
anti-pyruvate dehydrogenase in, 985
eosinophil major basic protein in, 939
lipoprotein oxidation in, 1060
Limiting dilution study, to study Klebsiella pneumoniae-reactive T cells in AS, 1277
Line profile analysis, in MRI in rheumatoid synovitis, 1610
Linkage, polyglot, polymorphism and, 1715
Linkage-disequilibrium model, shared-epitope DRB1 alleles in RA and, 1754
Lipid-binding protein, anti-apolipoprotein A1 in SLE and, 1655
Lipids
inositol, IgG receptors in autoimmune disease and, 306
lipoprotein oxidation, SSc and, 1060
Lipopolysaccharides
Chlamydia trachomatis in synovial membrane and, 1410
IL-6 production by IL-10 and IL-4 in RA and, 1046
nuclear factor-κB, in rheumatoid synovium and, 1762
Lipoprotein
high-density, anti-apolipoprotein A1 in SLE and, 1655
low-density, oxidized, cross-reactivity of anticardiolipin
autoantibodies with, 1382
Lyme borreliosis and, 565
oxidation of, SSc and, 1060
Liposomes, clodronate-containing, macrophages and, in rat adjuvant arthritis, 1777
Lipoxin A4, nitric oxide and, in polymorphonuclear neutrophil vascular cytotoxicity, 768
Liquid chromatography
gel-permeation, to study TGFβ1 in hyaluronan synthesis in synovial lining cells, 669
high performance, 517, 669, 699, 1040
Liquid hybridization, to study HTLV-1 in PM, 690
Listeria, guidelines for medical management of OA and, 1547
Liver
biopsy, 326, 1194
clodronate-containing liposomes, macrophages and, in rat adjuvant arthritis, 1777
disease, 1014, 1115, 1535
enzymes, 1799
function, 1595
immunosuppressive drugs during pregnancy and, 1722
NSAID, gastrointestinal tract and, 5
MTX and, 297, 326, 1194
in RA, 297, 326, 1194, 1595, 1799
toxicity, 297, 1014
Loading
knee OA and, 539, 1541
in stromelysin degradation of cartilage, 173
Localized synovial hemangioma, radiologic vignette, 559
Locking of the knee, guidelines for medical management of OA and, 1535
Long-term health outcomes, evaluative laboratory testing and, 1555
Long-term survival
cyclophosphamide, malignancy and, in RA, 1120
in SLE, 274
Loosening
of revision total hip replacement in RA, 1315
of total knee prosthesis, tuberculous and foreign-body granulomatous reactions in, 1325
Low back pain
in diagnosis of lumbar spinal stenosis, 1236
number of children and, 1232
Low-density lipoproteins, oxidation of
cross-reactivity of anticardiolipin autoantibodies with, 1382
SSc and, 1060
Low-dose corticosteroids, pulse cyclophosphamide, plasma
exchange and, in polyarteritis nodosa and Churg-Strauss syndrome, 1638
Low-dose cyclosporine, outcome measures in RA clinical trials and, 1568
Low-dose MTX
cytomegalovirus pneumonia and, 1528
prednisone and, in Wegener's granulomatosis, 608
in RA, 291, 819, 1581
Low-dose prednisone, MRI, PET and, in RA, 819
Low-dose steroids, hormone replacement, bone metabolism and, in postmenopausal RA, 901
Low-dose systemic glucocorticoid, MRI, PET and, in RA, 819
Lower extremities
cardiovascular health and fitness in end-stage OA and, 799
in diagnosis of lumbar spinal stenosis, 1236
in juvenile AS and JRA, 835
L-tryptophan, cognitive deficit in rheumatic diseases and, 1363
Lumbar spine
bone mineral density in hip OA and, 907
diagnosis of degenerative stenosis of, 1236
in gout, 139
in juvenile AS and JRA, 835
osteoporosis in RA and, 806
Lumbosacral spine, impairment of, in walking velocity in elderly, 343
Lung
antineutrophil cytoplasmic antibodies in mice and, 1375
biopsy, 437, 1855
disease, in scleroderma, 1345
eosinophil major basic protein in SSc and, 939
interstitial fibrosis of, HLA type and, 259
interstitium, antineutrophil cytoplasmic antibodies, circulating primed neutrophils and, in pulmonary capillaritis, 1855
PM, pulmonary fibrosis, hepatitis C and, 437
Lupus
antigen-based heteropolymers and, 190
fatigue in, 826
nucleosome-restricted antibodies in, 1485
patient subsets in, 1475
refractory cutaneous, cytarabine in, 1341
Lupus anticoagulant
in bone marrow transplantation in antiphospholipid syndrome, 115
human monoclonal antiphospholipid antibody and, 1068
Lupus-associated thrombosis, cross-reactivity of anticardiolipin autoantibodies with oxidized low-density lipoprotein and, 1382
Lupus erythematosus
cutaneous, photoexacerbation of, from ultraviolet emissions from photocopier, 1152
discoid, ear ulceration in, 1712
Lupus flares, dehydroepiandrosterone in, 1826
Lupus-like disorder, glomerulonephritis, C4 deficiency and, 1333
Lupus nephritis
Fc receptor IIa in, 1852
immunosuppressive drugs during pregnancy and, 1722
Lupus pregnancy, fatal pulmonary complication of, 710
Lupus vasculitis, antineutrophil cytoplasmic antibodies in SLE and, 633
Luteinizing hormone releasing hormone agonist, leuprolide, immunosuppressive drugs during pregnancy and, 1722
Lyme arthritis
autoimmune disease induction by microbial pathogens and, 458
chronic, 458
in European children and adolescents, 361
Lyme borreliosis and, 565
Lyme borreliosis, Sixth International Conference on, 565
Lyme disease
autoimmune disease induction by microbial pathogens and, 458
autoimmunity and, 301
in elderly with symptoms of DM, 1157
Lyme borreliosis, 565
Lymph nodes
biopsy, in nephrotic syndrome in RA and amyloidosis after azathioprine, 1851
in bone marrow transplantation in antiphospholipid syndrome, 115
in Epstein-Barr virus-associated Hodgkin's lymphoma in RA after MTX and cyclosporine, 867
popliteal, clodronate-containing liposomes, macrophages and, in rat adjuvant arthritis, 1777
Lymphatic sheath, periarteriolar, clodronate-containing liposomes, macrophages and, in rat adjuvant arthritis, 1777
Lymphocyte-mediated cytotoxicity, granzyme A, perforin mRNA and, in RA synovium, 477
Lymphocytes
in AIDS, 1701
autoimmune sialadenitis in Sjogren's syndrome and, 1077
cytokines, early response genes and, 877
large granular, in hematology of Felty's syndrome, 1252
Mls, autoimmune disease induction by microbial pathogens and, 458
peripheral blood, 254, 1187, 1589
in RA, 142, 254, 477, 867, 1187, 1346, 1589, 1701
T. See T cells
Lymphocytic infiltration
CAMPATH-1H in RA and, 254
HTLV-1 in PM and, 690
oral 2-chlorodeoxyadenosine in psoriatic arthritis and, 1604
Lymphocytic sialadenitis, focal, in Sjogren's syndrome, 869
Lymphocytopenia, oral 2-chlorodeoxyadenosine in psoriatic arthritis and, 1604
Lymphoid aggregates, activation markers of RA synovial membrane and, 1346
Lymphoid organs, peripheral, autoimmune disease induction by microbial pathogens and, 458
Lymphoid tissue, peripheral, IL-1 receptor antagonist in SLE and, 1055
Lymphoma
Hodgkin's, Epstein-Barr virus-associated, in RA, after MTX and cyclosporine, 867
HTLV-1 in PM, 690
non-Hodgkin's, mixed cryoglobulinemia and, 1859
T cell, carpal tunnel syndrome due to, 1707
Lymphopenia
CD4, large granular lymphocytes in hematology of Felty's syndrome and, 1242
persistent, in RA, 254, 1242
Lysates, synovial, antibodies to synovial antigens in early RA and, 1418
Lysozymes, antineutrophil cytoplasmic antibodies in SLE and, 633
Lysylpyridinoline, elastin and collagen degradation in SSc, 517
Lytic lesions, in spinal involvement in gout, 139